Peter Thiel joins funding round for peptide drug player in latest swing at emerging biotech market
For venture capitalists working in early-stage biotech, failures are more common than victories as investors search for novel pathways to treat well-trodden therapeutic areas. For the big-name investors, that’s equally true — but if your name’s Peter Thiel, a certain gravity and high expectations come with your money.
Billionaire tech entrepreneur and Facebook co-founder Thiel has joined a $35.4 million Series B round for Peptilogics, a peptide drug design and development biotech, as the company looks to expand on its lead anti-infective candidate and target more drugs for market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.